

NIÑO QUE SANGRA

- **DR: GUSTAVO CEA SANHUEZA.**
- **PEDIATRÍA HBV-UACH**



SANGRADO ANORMAL

- *Duración o volumen desproporcionado al evento.*
 - Epistaxis > de 15 minutos.
 - Persiste al día siguiente del dentista.
 - Menstruaciones de mas de 7 días.
 - Equimosis de tamaño mayor a una naranja.
 - Hemorragia en lactantes con vacunas o punciones.
 - Equimosis o hematomas desproporcionados al iniciar el gateo .
 - Equimosis en lugares distintos de la frente, codos y pretibiáles.



DOGMA 1

- *Cuando un niño ha sido sometido a alguna cirugía o extracciones dentales sin complicaciones hemorrágicas es muy improbable que tenga un trastorno hemorrágico congénito primario.*



DOGMA 2


- *Los hematomas musculares profundos y las hemartrosis en los niños son siempre anormales. Con o sin traumatismo.*



DOGMA 3

- *El hallazgo de equimosis antes de la edad de gateo o en sitios inhabituales debe alertar por posible maltrato.*

ALTERACIONES DE LA HEMOSTASIA PRIMARIA






TIPO DE SANGRADO.

- Púrpura cutáneo mucoso.
- Sangrado mucoso.
 - Epistaxis.
 - Hemorragia gingival.
 - Menorragia.
- Sangrado persistente.

ENFERMEDAD DE VON WILLEBRAND



FWD CLASIFICACIÓN.

Table 3 Classification of von Willebrand disease based on specific von Willebrand factor tests

VWD type	VWF:Ag	VWF:RCo	RCo/Ag	FVIII	Multimer pattern	Low-dose RIPA	Platelets
1	↓	↓	=	N or ↓	N	Absent	N
2A	↓	↓	RCo<Ag	N or ↓	Abnormal	Absent	N
2B	↓	↓	RCo<Ag	N or ↓	Abnormal	↑	N or ↓
2M	↓	↓	RCo<Ag	N or ↓	N	Absent	N
2N	N or ↓	N or ↓	=	<30 IU/dL	N	Absent	N
3	Absent	Absent	NA	<10 IU/dL	Absent	Absent	N

RIPA ristocetin-induced platelet aggregation, *VWF* von Willebrand factor, *VWD* von Willebrand disease, *NA* not applicable, *N* normal, *VWF:Ag* VWF antigen assay, *VWF:RCo* VWF ristocetin cofactor activity, *FVIII* factor VIII

TROMBOCITOPENIA

Table 1 Classification of thrombocytopenia in the neonate and child

Neonatal thrombocytopenia

Early onset (<72 h)
 Placental insufficiency
 Perinatal asphyxia
 Perinatal infection
 Disseminated intravascular coagulation
 Alloimmune
 Autoimmune
 Congenital infection
 Thrombosis
 Bone marrow infiltration replacement
 Kasabach–Merritt syndrome
 Metabolic disease
 Congenital/inherited

Late onset (>72 h)
 Sepsis
 Necrotizing enterocolitis
 Congenital infection
 Autoimmune
 Catheter-related thrombosis
 Kasabach–Merritt syndrome
 Metabolic disease
 Medication
 Congenital
 Inherited (large/normal/small platelets)

Childhood thrombocytopenia

Destructive thrombocytopenia
 Immune thrombocytopenia
 Medication
 Infection
 Hemolytic uremic syndrome
 Thrombotic thrombocytopenic purpura
 Catheter-related thrombosis
 Heart disease
 Disseminated intravascular coagulation
 Von Willebrand disease type 2B
 Kasabach–Merritt syndrome
 Hypersplenism
 Hypothermia
 Massive bleeding

Decreased production
 Inherited (large/normal/small platelets)
 Congenital aplastic anemia
 Congenital amegakaryopoiesis
 Bone marrow infiltration
 Vitamin B₁₂ deficiency
 Folic acid deficiency
 Acidosis
 Infection
 Medication



TROMBICITOPENIA NN PRECOZ (<72 h)

- Insuficiencia placentaria.
- Asfixia perinatal.
- Infecciones perinatales.
- CID.
- Aloimmune.
- Autoimmune.
- Congénita hereditaria.



TROMBOCITOPENIA NN ALOINMUNE.

- 1: 1000 a 1500 embarazos.
- IgG anti HPA-1a en 75%.
- Plaquetas < 20.000.
- HIC en 10 a 20% sin tratamiento
- RNT en lo demás sano.
- Plaquetas normales en la madre.




TROMBOCITOPENIA NN TARDIA (>72 h)

- Sepsis.
- Enterocolitis necrotizante.
- Infecciones congénitas.
- Autoinmune.
- Asociada a cateter.
- Enf. Metabólicas.
- Kasabach-Merrit.



TROMBOCITOPENIA DEL NIÑO

- *Por disminución de la producción:*
 - Hereditarias.
 - Anemia aplástica.
 - Infiltración medular.
 - Déficit de B₁₂ o foláto.
 - Infecciones.
 - Medicamentos.



TROMBOCITOPENIAS DEL NIÑO.


- *Por destrucción excesiva:*

- PTI
- Infecciones.
- SHU.
- CID.
- Hiperesplenismo.



PTI

- Plaquetas < 100.000.
- Manifestación significativa en 3%.
- Riesgo con plaquetas < 10.000.
- HIC 0.1% a 0.3%.
- Crónico > 12 meses.
- **Muy agudo y severo pero autolimitado.**



DISFUNCIONES PLAQUETARIAS.

- *Adquiridas.*
 - **Medicamentos.**
 - Insuficiencia renal.
 - Insuficiencia hepática.
 - Enfermedades neoplásicas.



DISFUNCIONES HEREDITARIAS.

- 1 a 2 casos por millón de niños.
- Solo en 50% → diagnóstico preciso.
 - Glanzmann 32%
 - Aspirin-like 21%
 - Receptores 17%
 - Storage pool 15%
 - B. Soulier 8%


DISFUNCIONES CLASIFICACION.

Table 4 Characteristic findings on light transmission aggregometry


Disorder	Platelet morphology	Platelet aggregation				
		Epinephrine	ADP	Collagen	Ristocetin	AA
Glanzmann	Normal	—	—	—	+	—
Bernard Soulier	Giant platelets	+	+	+	—	+
Aspirin	Normal	+	+	±	+	—
Storage pool disease						
Gray platelet syndrome	Large with decreased α -granules	+	—	—	+	+
δ -Granules deficiency	Decreased δ -granules	—	±	—	±	±

AA arachidonic acid, ADP adenosine 5'-diphosphate


ALGORITMO



ALTERACIONES DE LA HEMOSTASIA SECUNDARIA.



MODELO ACTUAL.





TIPO DE SANGRADO.

- *Hemorragias profundas:*
 - Hemartrosis.
 - Hematomas musculares.
 - HIC.
- Sangrado tardío.



HEMOFILIAS A Y B

- 1:5000 y 1:30000 hombres.
- 30% mutaciones “*de novo*”
- Severidad según nivel de factor:
 - Severa < 1%
 - Moderada 1 a 5 %
 - Leve 6 a 40%

OTROS TRASTORNOS HEREDITARIOS.

Table 1 Incidence, inheritance, clinical manifestations, and therapeutic modalities, for both the congenital coagulation factor deficiencies and the fibrinolytic defects [4, 6, 15]

	Incidence	Inheritance	Clinical manifestations	Therapeutic modalities
Congenital coagulation factor deficiencies				
Hypo-, or afibrinogenemia (FI deficiency)	1 per 1,000,000	AR	Bleeding of umbilical cord, in gastro-intestinal tract, in genito-urinary tract, in CNS, posttraumatic/post-surgery bleeding, mucocutaneous bleeding or joint bleeding (rare)	Pd-fibrinogen conc. Plasma
FII deficiency (prothrombin deficiency)	1 per 2,000,000	AR	Bleeding of muscle or joint, mucocutaneous bleeding, or CNS bleeding (rare)	Prothrombin complex conc. Plasma
FV deficiency	1 per 1,000,000	AR	Mucocutaneous bleeding, joint bleeding (rare) or umbilical cord bleeding (rare)	Plasma
FVII deficiency	1 per 500,000	AR	Bleeding of joint, CNS bleeding or mucocutaneous bleeding	Pd-FVII conc. Rec. FVIIa conc.
FVIII deficiency (hemophilia A)	1 per 5,000 males	X-linked	Bleeding of joint or muscle, in CNS, posttraumatic/post-surgery bleeding or mucocutaneous bleeding	Rec. FVIII conc. Pd-FVIII conc.
FIX deficiency (hemophilia B)	1 per 30,000 males	X-linked	Bleeding of joint or muscle, in CNS, posttraumatic/post-surgery bleeding or mucocutaneous bleeding	Rec. FIX conc. Pd-FIX conc.
FX deficiency	1 per 1,000,000	AR	Mucocutaneous bleeding, posttraumatic/post-surgery bleeding, umbilical cord or joint bleeding (rare)	Prothrombin complex conc. Plasma
FXI deficiency (hemophilia C)	1 per 1,000,000	AR	Posttraumatic bleeding/post-surgery bleeding, mucocutaneous bleeding	Pd-FXI conc. Plasma
FXII deficiency	25 per 1,000	AR	None	Not necessary
FXIII deficiency	1 per 1,000,000	AR	Bleeding of umbilical cord or in CNS, poor wound healing	Pd-FXIII conc. or plasma
Congenital fibrinolytic defects				
Antiplasmin deficiency	Rare	AR	Mucocutaneous bleeding, posttraumatic/post-surgery re-bleeding, bleeding of joint, umbilical cord or in CNS	Antifibrinolytic drugs Plasma
Plasminogen activator inhibitor 1 deficiency	Rare	AR	Mucocutaneous bleeding, posttraumatic/post-surgery re-bleeding, bleeding of joint or in CNS	Antifibrinolytic drugs


FV factor V, *AR* autosomal recessive, *CNS* central nervous system, *conc.* concentrate, *Pd* plasma-derived, *rec.* recombinant




TRASTORNOS ADQUIRIDOS.

- Déficit de vitamina K.
- Anticoagulantes.
- CID.
- Enfermedad hepática severa.

ALGORITMO.





FIN